PHOXILLUMBK4/2.5 (Baxter Healthcare Corporation)


Welcome to the PulseAid listing for the PHOXILLUM drug offered from Baxter Healthcare Corporation. This Blood Coagulation Factor [EPC],Increased Coagulation Factor Activity [PE],Calcium [Chemical/Ingredient],Cations, Divalent [Chemical/Ingredient],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Baxter Healthcare Corporation
NON-PROPRIETARY NAME: calcium chloride, magnesium chloride, sodium chloride, potassium chloride, sodium phosphate dibasic dihydrate, and sodium bicarbonate
SUBSTANCE NAME: CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC DIHYDRATE; SODIUM BICARBONATE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Blood Coagulation Factor [EPC],Increased Coagulation Factor Activity [PE],Calcium [Chemical/Ingredient],Cations, Divalent [Chemical/Ingredient],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA]
ROUTE: INTRAVENOUS
DOSAGE FORM: SOLUTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2015-01-13
END MARKETING DATE: 0000-00-00


PHOXILLUM BK4/2.5 HUMAN PRESCRIPTION DRUG Details:

Item DescriptionPHOXILLUM BK4/2.5 from Baxter Healthcare Corporation
LABELER NAME: Baxter Healthcare Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: .184; .153; 6.019; .298; .178; 2.688(g/L; g/L; g/L; g/L; g/L; g/L)
START MARKETING DATE: 2015-01-13
END MARKETING DATE: 0000-00-00
PRODUCT ID: 24571-116_de471206-dcf9-4219-8282-1d6e48141f93
PRODUCT NDC: 24571-116
APPLICATION NUMBER: NDA207026

Other CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC DIHYDRATE; SODIUM BICARBONATE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Baxter Healthcare CorporationPHOXILLUM